Recital 9, Regulation (EU) 2022/315

In forcesince 17 Dec 2021

In order to ensure that medicinal products re-imported into the Union are not placed on the market elsewhere than Northern Ireland, Cyprus, Ireland and Malta, it is necessary to ensure that the repositories system provide an alert when the medicinal product is verified elsewhere in the Union. Wholesalers in Northern Ireland, Cyprus, Ireland and Malta should also perform checks of shipments of medicinal products intended for the United Kingdom market received from manufacturers, marketing authorisation holders and wholesalers designated by the marketing authorisation holder to ensure the products they receive comply with the rules on safety features.